Estimation of the optimal radiotherapy utilization rate for childhood neuroblastoma
- PMID: 38806114
- DOI: 10.1016/j.radonc.2024.110343
Estimation of the optimal radiotherapy utilization rate for childhood neuroblastoma
Abstract
Background and purpose: The optimal utilization rate of radiotherapy (oRUR) serves as a benchmark for assessing service demand and improving access to cancer care. While it is estimated that approximately 50 % of adult cancer patients require external beam radiotherapy during their treatment, there is a scarcity of data regarding the optimal use of radiotherapy in pediatric cancer. In this study, we adopted an established method and developed a model to estimate the oRUR in childhood neuroblastoma.
Materials and methods: We developed a decision tree model to calculate the oRUR using indications for radiotherapy and corresponding epidemiological data collected through systematic review and meta-analysis. Sensitivity analyses were performed to evaluate the impact of variations in radiotherapy indications between treatment protocols and variables in the model. We calculated and compared the oRUR for global, high-income, and low- and middle-income settings.
Results: The oRUR for pediatric neuroblastoma was 64 % (95 % CI: 58 %-71 %) in the global setting, 50 % in high-income countries, and 68 % in low- and middle-income countries. The impact of variation in radiotherapy indications between major international treatment protocols was negligible.
Conclusion: The knowledge of oRUR is crucial for evaluating current practices, identifying gaps in access, and planning future radiotherapy services for treating childhood cancer. Based on our results, 64 % of children with neuroblastoma have an indication for radiotherapy. Patients in low- and middle-income countries have more indications for radiotherapy than those in high-income countries, due to a more adverse tumour stage distribution caused by limited access to healthcare resources.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
What is the optimal radiotherapy utilization rate for lung cancer?-a systematic review.Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S163-S171. doi: 10.21037/tlcr.2019.08.12. Transl Lung Cancer Res. 2019. PMID: 31673521 Free PMC article. Review.
-
Colorectal cancer radiotherapy utilization rate in a low-middle income country - a multicenter study in Indonesia.Contemp Oncol (Pozn). 2025;29(1):113-122. doi: 10.5114/wo.2025.149236. Epub 2025 Apr 9. Contemp Oncol (Pozn). 2025. PMID: 40330449 Free PMC article.
-
The Practice of Paediatric Radiation Oncology in Low- and Middle-income Countries: Outcomes of an International Atomic Energy Agency Study.Clin Oncol (R Coll Radiol). 2021 Apr;33(4):e211-e220. doi: 10.1016/j.clon.2020.11.004. Epub 2020 Nov 26. Clin Oncol (R Coll Radiol). 2021. PMID: 33250288 Review.
-
Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.Lancet Oncol. 2019 Jul;20(7):915-923. doi: 10.1016/S1470-2045(19)30308-0. Epub 2019 May 28. Lancet Oncol. 2019. PMID: 31151906 Free PMC article.
-
The Evidence for External Beam Radiotherapy in High-Risk Neuroblastoma of Childhood: A Systematic Review.Clin Oncol (R Coll Radiol). 2019 Mar;31(3):182-190. doi: 10.1016/j.clon.2018.11.031. Epub 2018 Dec 1. Clin Oncol (R Coll Radiol). 2019. PMID: 30509728
Cited by
-
Overcoming the blood-brain barrier (BBB) in pediatric CNS tumors: immunotherapy and nanomedicine-driven strategies.Med Oncol. 2025 Aug 19;42(10):431. doi: 10.1007/s12032-025-02984-y. Med Oncol. 2025. PMID: 40828479 Review.
-
Role and practical guidelines for the use of radiotherapy in neuroblastoma - a narrative review of literature and clinical trial protocols.Rep Pract Oncol Radiother. 2025 Aug 7;30(3):424-438. doi: 10.5603/rpor.106279. eCollection 2025. Rep Pract Oncol Radiother. 2025. PMID: 40919252 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical